Sectra Completes Oxipit Acquisition (2026-04-15)
Sectra / Oxipit — Market Signals | Marketstrat Marketstrat|Market Signals Deal Intelligence · MedTech Event-Driven Analysis No. 02 · April 2026 M&A · Radiology AI · EU → EU Sectra pulls autonomous AI inside the enterprise imaging stack. Completion of the Oxipit acquisition consolidates the independent autonomous chest X-ray AI market into two platforms in […]
Neuropacs De Novo: First FDA-Authorized AI Pathway for Chronic Neurodegenerative Disease Differentiation
Event Date: April 3, 2026 (FDA decision) | April 7, 2026 (public announcement) Marketstrat® · Markintel Market Signals Neuropacs De Novo: First FDA-Authorized AI Pathway for Chronic Neurodegenerative Disease Differentiation Published: April 16, 2026 Sector: MedTech & Digital Health Focus: Neurological Imaging AI FDA grants De Novo classification to neuropacs™ (April 3, 2026) Creates a […]
The Highest-Value AI Frontier Is Shifting from Interpretation to Acquisition
Innovation Hook · Butterfly Network (NYSE: BFLY) The Highest-Value AI Frontier Is Shifting from Interpretation to Acquisition FDA clearance of first blind-sweep gestational age tool · March 30, 2026 Most radiology AI analyzes images after a skilled operator captures them. Butterfly’s GA Tool automates the scan itself — eliminating the operator skill requirement entirely. That […]
RadNet Acquires Gleamer: The Radiology AI Platform Consolidation Thesis Takes Shape
This is an excerpt of Marketstrat’s full strategic analysis. The complete research note — including detailed competitive landscape analysis, integration risk assessment, and company profiles — is available to clients. EXECUTIVE SUMMARY On March 2, 2026, RadNet, Inc. (NASDAQ: RDNT) completed its acquisition of Gleamer SAS, a Paris-based radiology AI company, for up to €230 […]
GE HealthCare: Procedure-Room AI Platformization Accelerates
Date: February 11, 2026 | Company: GE Healthcare (GEHC) | Sector Lens: Interventional Imaging + Workflow AI | Cath Lab Economics | Platform Procurement GE HealthCare’s Allia Moveo FDA clearance/CE Mark is a signal that AI is embedding directly into interventional imaging workflows. The same-week Medtronic–CathWorks deal highlights a parallel consolidation of angiography-derived decision support, […]
ScreenPoint Medical: MASAI makes breast AI procurement-grade screening infrastructure
Date: February 5, 2026 | Sector Lens: Medical Imaging + AI (Breast screening / mammography workflow) ScreenPoint Medical’s Transpara-enabled MASAI randomized trial published its primary endpoint in The Lancet, showing a non-inferior interval cancer rate versus standard double reading with higher sensitivity and unchanged specificity. We interpret this as a market signal that breast AI […]
Siemens Healthineers: MRI’s next battleground is “constraint removal,” not “image quality.”
Date: February 4, 2026 | Sector Lens: MRI + Embedded AI | Provider ops | Sustainability/TCO | Siting & infrastructure Siemens’ FDA-cleared 70cm MAGNETOM Flow platform signals an MRI procurement shift toward constraint removal—helium exposure, siting friction, and energy intensity—supported by embedded workflow and reconstruction AI. The strategic question for providers is not “better images,” […]
MRI acquisition automation moves from “pilot” to provider-backed platform
Date: January 16, 2026 | Topic: Medical Imaging & MRI | Company: Vista AI Vista AI closed a $29.5M Series B with a notable twist: multiple strategic health systems participated—an unusually strong market signal that MRI automation is becoming operational infrastructure, not just “AI at the reading workstation.” Vista AI is leveraging an FDA-cleared platform […]
Aidoc: FDA “multi-triage” clearance marks the platform bundling phase
Date: January 26, 2026 | Sector Lens: Medical Imaging + AI | Radiology workflow + acute triage (CADt)| Company: Aidoc Aidoc received FDA 510(k) clearance for BriefCase‑Triage: CARE Multi‑triage CT Body, enabling a single abdominal CT triage workflow spanning 14 acute findings (11 newly cleared + 3 previously cleared). This is a clean “market signal” […]
The Battle for the Cath Lab Cockpit: Why Philips’ Acquisition of SpectraWAVE Resets the Interventional Stack
Date: December 23, 2025 | Topic: Medical Imaging & Interventional Strategy | Company: Royal Philips (NYSE: PHG) Philips’ acquisition of SpectraWAVE is not a product expansion—it is a platform defense designed to close the company’s only major strategic gap against Abbott and Boston Scientific: the integrated high-resolution imaging stack. Executive Brief: The “So What” Philips’ […]
